Fluvoxamine enhances prefrontal dopaminergic neurotransmission in adrenalectomized/castrated mice via both 5-HT reuptake inhibition and σ1 receptor activation
Fluvoxamine, a selective serotonin (5-HT) reuptake inhibitor (SSRI) and an agonist for the σ1 receptors, increases extracellular monoamines in the prefrontal cortex, but it is not known whether the σ1 receptor is involved in the neurochemical effect of fluvoxamine.
In view of the fact that circulating steroids exert a tonic modulatory effect on σ1 receptor-mediated effects, the present study examines the effects of fluvoxamine on prefrontal extracellular monoamine levels in adrenalectomized/castrated mice lacking the peripheral sources of steroids.
Fluvoxamine-induced increases in the extracellular levels of dopamine (DA), but not of 5-HT and noradrenaline, were significantly higher in adrenalectomized/castrated than in sham-operated mice, and this effect was blocked by BD1047, a selective σ1 receptor antagonist. In contrast, the effects of paroxetine, an SSRI without affinity for the σ1 receptors, and (+)-SKF-10,047, a selective σ1 receptor agonist, on the extracellular monoamine levels did not differ between adrenalectomized/castrated and sham-operated mice, while the increase in extracellular DA levels induced by co-administration of these drugs was higher in adrenalectomized/castrated than in the control mice. Moreover, fluvoxamine increased c-Fos expression, a marker of neuronal activity, in the prefrontal cortex of adrenalectomized/castrated mice, and this effect was blocked by BD1047. The similar increase in c-Fos expression was observed by co-administration of paroxetine and (+)-SKF-10,047.
These findings suggest that fluvoxamine enhances prefrontal dopaminergic neurotransmission via both 5-HT reuptake inhibition and σ1 receptor activation under the circulating neuroactive steroid-deficient conditions.
KeywordsFluvoxamine σ1 receptor c-Fos Adrenalectomy/castration Dopamine (DA) Prefrontal cortex
This study was supported in part by a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (from the Ministry of Education, Culture, Sports, Science and Technology of Japan).
Conflicts of interest
The authors state no conflicts of interest.
- Corpéchot C, Young J, Calvel M, Wehrey C, Veltz JN, Touyer G, Mouren M, Prasad VVK, Banner C, Sjovall J, Baulieu EE, Robel P (1993) Neurosteroids: 3α-hydroxy-5α-pregnan-20-one and its precursors in the brain, plasma, and steroidogenic glands of male and female rats. Endocrinology 133:1003–1009PubMedCrossRefGoogle Scholar
- Franklin KBJ, Paxinos G (1997) The mouse brain in stereotaxic coordinates. Academic, San DiegoGoogle Scholar
- Ishikawa M, Ishiwata K, Ishii K, Kimura Y, Sakata M, Naganawa M, Oda K, Miyatake R, Fujisaki M, Shimizu E, Shirayama Y, Iyo M, Hashimoto K (2007) High occupancy of sigma-1 receptors in the human brain after single oral administration of fluvoxamine: a positron emission tomography study using [11C]SA4503. Biol Psychiatry 62:878–883PubMedCrossRefGoogle Scholar
- Paslakis G, Luppa P, Gilles M, Kopf D, Hamann-Weber B, Lederbogen F, Deuschle M (2010) Venlafaxine and mirtazapine treatment lowers serum concentrations of dehydroepiandrosterone-sulfate in depressed patients remitting during the course of treatment. J Psychiatr Res 44:556–560PubMedCrossRefGoogle Scholar
- Volonté M, Ceci A, Borsini F (1995) Effect of the 5-hydroxytryptamine3 receptor antagonist itasetron (DAU 6215) on (+)-N-allylnormetazocine-induced dopamine release in the nucleus accumbens and in the corpus striatum of the rat: an in vivo microdialysis study. J Pharmacol Exp Ther 275:358–367PubMedGoogle Scholar
- Zhang W, Perry KW, Wong DT, Potts BD, Bao J, Tollefson GD, Bymaster FP (2000) Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology 23:250–262PubMedCrossRefGoogle Scholar